Lisata Therapeutics up on EMA orphan tag for cancer drug candidate

Lisata Therapeutics

17/10/2023 16:28

** Lisata Therapeutics  LSTA.O  up 5.7% at $2.24
    ** Company's lead product candidate, LSTA1, granted "orphan
drug" designation by European Medicines Agency for treatment of
pancreatic cancer
    ** LSTA1 is an investigational drug designed to activate a
novel uptake pathway that allows co-administered anti-cancer
drugs to penetrate solid tumors more effectively
    ** Benefits of orphan drug tag include potential for up to
10-year EU market exclusivity upon regulatory approval of
therapy
    ** U.S. health regulator in August also granted orphan drug
tag for LSTA1 to treat a type of brain tumor
    ** Currently, LSTA1 is being tested in multiple ongoing and
planned clinical studies in a variety of solid tumor types,
including in combination with a variety of anti-cancer regimens
- company
    ** Including session's gain, stock down 11.5% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com))